Sodium-Glucose Co-Transporter 2 Inhibitors Increase Serum Level Of Total Procollagen Type 1 Amino-Terminal Propeptide And Bone Strength In Japanese Patients With Type 2 Diabetes Mellitus
JOURNAL OF ENDOCRINOLOGY AND METABOLISM(2020)
摘要
Background: Diabetes mellitus is known to be associated with an increased risk of bone fracture. We investigated the effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on bone strength and density in type 2 diabetic patients.Methods: Nineteen Japanese patients with type 2 diabetes mellitus were administered 2.5 mg/day of luseogliflozin or 5 mg/day of dapagliflozin for 6 months. Serum levels of tartrate-resistant acid phosphatase 5b (TRACP-5b), an osteoclastic marker, and total procollagen type 1 amino-terminal propeptide (P1NP), a bone formation marker, were measured and compared with those before the treatment. Bone strength was measured by quantitative ultrasound (QUS), and bone density was evaluated by dual-energy X-ray absorptiometry (DEXA).Results: SGLT2 inhibitors significantly increased the calcaneal bone strength as measured by QUS compared to that in young adult mean. However, there was no effect in the lumbar spine density as measured by DEXA after administration. The drug treatment had no effect on serum TRACP-5b, but significantly increased serum P1NP.Conclusions: The results imply that the SGLT2 inhibitors improve bone strength while the inhibitors had no effect on bone density. These results suggest that the increase in bone strength was due to improved bone quality through an increase in serum P1NP level.
更多查看译文
关键词
SGLT2 inhibitor, Bone fracture, Quantitative ultrasound analysis, Dual-energy X-ray absorptiometry, Procollagen type 1 amino-terminal propeptide
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络